Common irAEs associated with ICI therapy include thyroid dysfunctions, both hypothyroidism and hyperthyroidism or thyrotoxicosis, especially while administering anti-PD-1 or anti-PD-L1 antibodies. Here, PDCD1 is linked to hyperthyroidism.